Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers.

SCHEEN, André; DELANAYE, Pierre

doi:10.1016/j.diabet.2021.101315

Article (Scientific journals)

Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers.

SCHEEN, André; DELANAYE, Pierre

2022 • In Diabetes and Metabolism, 48 (2), p. 101315

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/289556

DOI
10.1016/j.diabet.2021.101315

PubMed
34910981

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2022 acute renal injury AS PD.pdf

Publisher postprint (569.95 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Acute kidney injury; Chronic kidney disease; RAAS inhibitor; SGLT2 inhibitor; Type 2 diabetes; Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology; General Medicine

Abstract :

[en] Renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are two pharmacological classes that proved a remarkable nephroprotective effect, yet a risk of acute kidney injury (AKI) was also pointed out. In 2016, the US Food and Drug Administration recommended caution with the concomitant use of these medications. While the literature devoted to RAAS blockers remained surprisingly limited, numerous articles were published in recent years with SGLT2is. Safety analyses of large prospective cardiorenal trials showed a reduced rather than an increased number of AKI events in patients with type 2 diabetes treated with SGLT2is compared with those treated with placebo, despite the fact that a majority of patients received RAAS blockers at baseline. Interestingly, retrospective observational studies confirmed these reassuring findings in real-life conditions in more heterogeneous and possibly more frailty populations also commonly treated with RAAS blockers by showing a reduced risk of AKI with SGLT2is compared with other glucose-lowering drugs. Currently, there are no evidence of an increased risk of AKI with RAAS blocker-SGLT2i combinations in absence of haemodynamic instability. Several underlying mechanisms could explain a decreased rather than an increased risk of AKI with SGLT2is, including in patients treated with RAAS blockers.

Disciplines :

Endocrinology, metabolism & nutrition
Urology & nephrology
Pharmacy, pharmacology & toxicology

Author, co-author :

SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie

Language :

English

Title :

Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers.

Publication date :

March 2022

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Elsevier Masson s.r.l., France

Volume :

Issue :

Pages :

101315

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S1262363621000987?httpAccept=text/xml

Available on ORBi :

since 11 April 2022

Statistics

Number of views

74 (1 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kidney Disease: improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2 (2012), 1–138.
Advani, A., Acute kidney injury: a bona fide complication of diabetes. Diabetes 69 (2020), 2229–2237.
Hapca, S., Siddiqui, M.K., Kwan, R.S.Y., Lim, M., Matthew, S., Doney, A.S.F., et al. The relationship between AKI and CKD in patients with type 2 diabetes: an observational cohort study. J Am Soc Nephrol 32 (2021), 138–150.
Xu, Y., Surapaneni, A., Alkas, J., Evans, M., Shin, J.I., Selvin, E., et al. Glycemic control and the risk of acute kidney injury in patients with type 2 diabetes and chronic kidney disease: parallel population-based cohort studies in U.S. and Swedish routine care. Diabetes Care 43 (2020), 2975–2982.
Sawhney, S., Fraser, S.D., Epidemiology of AKI: utilizing large databases to determine the burden of AKI. Adv Chronic Kidney Dis 24 (2017), 194–204.
Legrand, M., Rossignol, P., Cardiovascular consequences of acute kidney injury. N Engl J Med 382 (2020), 2238–2247.
Thakar, C.V., Christianson, A., Himmelfarb, J., Leonard, A.C., Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 6 (2011), 2567–2572.
See, E.J., Jayasinghe, K., Glassford, N., Bailey, M., Johnson, D.W., Polkinghorne, K.R., et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int 95 (2019), 160–172.
Chawla, L.S., Eggers, P.W., Star, R.A., Kimmel, P.L., Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371 (2014), 58–66.
Palevsky, P.M., Liu, K.D., Brophy, P.D., Chawla, L.S., Parikh, C.R., Thakar, C.V., et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61 (2013), 649–672.
Vanmassenhove, J., Kielstein, J., Jorres, A., Van Biesen, W., Management of patients at risk of acute kidney injury. Lancet 389 (2017), 2139–2151.
Vijayan, A., Tackling AKI: prevention, timing of dialysis and follow-up. Nature Rev Nephrol 17 (2021), 87–88.
Brenner, B.M., Lawler, E.V., Mackenzie, H.S., The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 49 (1996), 1774–1777.
Abdi, R., Brenner, B.M., Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?. Semin Nephrol 24 (2004), 141–146.
Neuen, B.L., Young, T., Heerspink, H.J.L., Neal, B., Perkovic, V., Billot, L., et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7 (2019), 845–854.
Delanaye, P., Scheen, A.J., Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin Pharmacother 20 (2019), 277–294.
Scheen, A.J., Delanaye, P., Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Rev Endocrinol Metab, 2021 In press.
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41 (2020), 255–323.
Sharma, N., Anders, H.J., Gaikwad, A.B., Fiend and friend in the renin angiotensin system: an insight on acute kidney injury. Biomed Pharmacother 110 (2019), 764–774.
Mansfield, K.E., Nitsch, D., Smeeth, L., Bhaskaran, K., Tomlinson, L.A., Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open, 6, 2016, e012690.
Jones, M., Tomson, C., Acute kidney injury and 'nephrotoxins': mind your language. Clin Med (Lond) 18 (2018), 384–386.
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin (latest access October 20, 2021).
Baker, M.L., Perazella, M.A., SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?. J Nephrol 33 (2020), 985–994.
Lameire, N.H., Levin, A., Kellum, J.A., Cheung, M., Jadoul, M., Winkelmayer, W.C., et al. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int 100 (2021), 516–526.
Cherney, D.Z.I., Dagogo-Jack, S., McGuire, D.K., Cosentino, F., Pratley, R., Shih, W.J., et al. Kidney outcomes using a sustained >/=40% decline in eGFR: a meta-analysis of SGLT2 inhibitor trials. Clin Cardiol 44 (2021), 1139–1143.
Schoolwerth, A.C., Sica, D.A., Ballermann, B.J., Wilcox, C.S., Council on the Kidney in Cardiovascular, D, the Council for High Blood Pressure Research of the American Heart, A, Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104 (2001), 1985–1991.
Lv, X., Zhang, Y., Niu, Y., Song, Q., Zhao, Q., Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore), 97, 2018, e0256.
Vejakama, P., Thakkinstian, A., Lertrattananon, D., Ingsathit, A., Ngarmukos, C., Attia, J., Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 55 (2012), 566–578.
Cai, J., Huang, X., Zheng, Z., Lin, Q., Peng, M., Shen, D., Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis. Nephrol Dial Transplant 33 (2018), 1968–1976.
Hricik, D.E., Dunn, M.J., Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1 (1990), 845–858.
Bakris, G.L., Weir, M.R., Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 160 (2000), 685–693.
Holtkamp, F.A., de Zeeuw, D., Thomas, M.C., Cooper, M.E., de Graeff, P.A., Hillege, H.J., et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80 (2011), 282–287.
Tomson, C., Tomlinson, L.A., Stopping RAS inhibitors to minimize AKI: more harm than good?. Clin J Am Soc Nephrol 14 (2019), 617–619.
Disease, Kidney, Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3 (2013), 1–150.
Tonneijck, L., Muskiet, M.H., Smits, M.M., van Bommel, E.J., Heerspink, H.J., van Raalte, D.H., et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28 (2017), 1023–1039.
Palmer, S.C., Mavridis, D., Navarese, E., Craig, J.C., Tonelli, M., Salanti, G., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385 (2015), 2047–2056.
Lapi, F., Azoulay, L., Yin, H., Nessim, S.J., Suissa, S., Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ, 346, 2013, e8525.
Dreischulte, T., Morales, D.R., Bell, S., Guthrie, B., Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 88 (2015), 396–403.
Chaumont, M., Pourcelet, A., van Nuffelen, M., Racape, J., Leeman, M., Hougardy, J.M., Acute kidney injury in elderly patients with chronic kidney disease: do angiotensin-converting enzyme inhibitors carry a risk?. J Clin Hypertens 18 (2016), 514–521.
Feidakis, A., Panagiotou, M.R., Tsoukakis, E., Bacharaki, D., Gounari, P., Nikolopoulos, P., et al. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on acute kidney injury in emergency medical admissions. J Clin Medi, 10, 2021.
Palevsky, P.M., Zhang, J.H., Seliger, S.L., Emanuele, N., Fried, L.F., Study VN-D. Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade. Clin J Am Soc Nephrol 11 (2016), 1944–1953.
Ren, F., Tang, L., Cai, Y., Yuan, X., Huang, W., Luo, L., et al. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy. Ren Fail 37 (2015), 548–561.
Mayer, G.J., Wanner, C., Weir, M.R., Inzucchi, S.E., Koitka-Weber, A., Hantel, S., et al. Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int 96 (2019), 489–504.
Tomlinson, L.A., Abel, G.A., Chaudhry, A.N., Tomson, C.R., Wilkinson, I.B., Roland, M.O., et al. ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study. PLoS ONE, 8, 2013, e78465.
Bedford, M., Farmer, C.K., Irving, J., Stevens, P.E., Acute kidney injury: an acceptable risk of treatment with renin-angiotensin system blockade in primary care?. Can J Kidney Health Dis, 2, 2015, 14.
Sud, M., Ko, D.T., Chong, A., Koh, M., Azizi, P.M., Austin, P.C., et al. Renin-angiotensin-aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease. Pharmacotherapy, 2021; Sep 8, 10.1002/phar.2624.
Mansfield, K.E., Douglas, I.J., Nitsch, D., Thomas, S.L., Smeeth, L., Tomlinson, L.A., Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis. Clin Epidemiol 10 (2018), 187–202.
Yacoub, R., Patel, N., Lohr, J.W., Rajagopalan, S., Nader, N., Arora, P., Acute kidney injury and death associated with renin angiotensin system blockade in cardiothoracic surgery: a meta-analysis of observational studies. Am J Kidney Dis 62 (2013), 1077–1086.
Mark, P.B., Papworth, R., Ramparsad, N., Tomlinson, L.A., Sawhney, S., Black, C., et al. Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors. Br J Clin Pharmacol 86 (2020), 121–131.
Chen, J.Y., Tsai, I.J., Pan, H.C., Liao, H.W., Neyra, J.A., Wu, V.C., et al. The impact of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on clinical outcomes of acute kidney disease patients: a systematic review and meta-analysis. Front Pharmacol, 12, 2021, 665250.
Siew, E.D., Parr, S.K., Abdel-Kader, K., Perkins, A.M., Greevy, R.A. Jr, Vincz, A.J., et al. Renin-angiotensin aldosterone inhibitor use at hospital discharge among patients with moderate to severe acute kidney injury and its association with recurrent acute kidney injury and mortality. Kidney Int 99 (2021), 1202–1212.
Perazella, M.A., Coca, S.G., Three feasible strategies to minimize kidney injury in 'incipient AKI'. Nature Rev Nephrol 9 (2013), 484–490.
Cheungpasitporn, W., Thongprayoon, C., Srivali, N., O'Corragain, O.A., Edmonds, P.J., Ungprasert, P., et al. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant 30 (2015), 978–988.
Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
Delanaye, P., Scheen, A.J., The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection. Diabetes Metab, 47, 2021, 101285.
Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Giugliano, D., Longo, M., Caruso, P., Maiorino, M.I., Bellastella, G., Esposito, K., Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab 23 (2021), 1672–1676.
American Diabetes A. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 44 (2021), S111–SS24.
Kidney Disease: improving Global Outcomes Diabetes Work G. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98 (2020), S1–S115.
Phadke, G., Kaushal, A., Tolan, D.R., Hahn, K., Jensen, T., Bjornstad, P., et al. Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report. Am J Kidney Dis 76 (2020), 144–147.
Watanabe, S., Sawa, N., Mizuno, H., Yamanouchi, M., Suwabe, T., Hoshino, J., et al. Development of osmotic vacuolization of proximal tubular epithelial cells following treatment with sodium-glucose transport protein 2 inhibitors in type II diabetes mellitus patients-3 case reports. CEN Case Rep 10 (2021), 563–569.
Ryan, R., Choo, S., Willows, J., Walker, J., Prasad, K., Tez, D., Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clin Kidney J 14 (2021), 1020–1022.
Hassani-Ardakania, K., Lipman, M.L., Laporta, D., Yu, O.H.Y., A case of severe acute kidney injury exacerbated by canagliflozin in a patient with type 2 diabetes. Case Rep Endocrinol, 2019, 2019, 8639629.
Pleros, C., Stamataki, E., Papadaki, A., Damianakis, N., Poulidaki, R., Gakiopoulou, C., et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep 7 (2018), 17–20.
Scheen, A.J., An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 18 (2019), 295–311.
Scheen, A.J., Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opin Drug Safety 19 (2020), 243–256.
Milder, T.Y., Stocker, S.L., Day, R.O., Greenfield, J.R., Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf 43 (2020), 1211–1221.
Desai, M., Yavin, Y., Balis, D., Sun, D., Xie, J., Canovatchel, W., et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 19 (2017), 897–900.
Perlman, A., Heyman, S.N., Matok, I., Stokar, J., Muszkat, M., Szalat, A., Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 27 (2017), 1108–1113.
Zhenwei, F., Jia, S., Xiujin, S., et al. Risks of acute kidney injury due to sodium glucose co-transporter 2 inhibitors: a study based on the related data in the US Food and Drug Administration Adverse Event Reporting System. Adverse Drug Reactions J 21 (2019), 190–197.
Katsuhara, Y., Ogawa, T., Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database. Clin Drug Investig 40 (2020), 645–652.
Alomar, M., Tawfiq, A.M., Hassan, N., Palaian, S., Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf, 11, 2020, 2042098620938595.
Donnan, J.R., Grandy, C.A., Chibrikov, E., Marra, C.A., Aubrey-Bassler, K., Johnston, K., et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open, 9, 2019, e022577.
Gilbert, R.E., Thorpe, K.E., Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 21 (2019), 1996–2000.
Qiu, M., Ding, L.L., Zhang, M., Zhou, H.R., Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res, 18, 2021, 14791641211011016.
Bai, Y., Jin, J., Zhou, W., Zhang, S., Xu, J, The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 31 (2021), 1365–1374.
Cahn, A., Raz, I., Bonaca, M., Mosenzon, O., Murphy, S.A., Yanuv, I., et al. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab 22 (2020), 1357–1368.
Cahn, A., Mosenzon, O., Wiviott, S.D., Rozenberg, A., Yanuv, I., Goodrich, E.L., et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study. Diabetes Care 43 (2020), 468–475.
Heerspink, H.J.L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis, 2021;May 23 S0272-6386(21)00626-0.
Heerspink, H.J., Cherney, D., Postmus, D., Stefansson, B.V., Chertow, G.M., Dwyer, J.P., et al. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int, 2021;Sep 22 S0085-2538(21)00865-6.
Lin, D.S., Lee, J.K., Chen, W.J., Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab 106 (2021), 2133–2145.
Zhao, M., Sun, S., Huang, Z., Wang, T., Tang, H., Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. Clin J Am Soc Nephrol 16 (2020), 70–78.
Pelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., Gamble, J.M., Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf, 12, 2021, 2042098621989134.
Menne, J., Dumann, E., Haller, H., Schmidt, B.M.W., Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med, 16, 2019, e1002983.
Caparrotta, T.M., Greenhalgh, A.M., Osinski, K., Gifford, R.M., Moser, S., Wild, S.H., et al. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. Diabetes Ther 12 (2021), 991–1028.
Nadkarni, G.N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40 (2017), 1479–1485.
Ueda, P., Svanstrom, H., Melbye, M., Eliasson, B., Svensson, A.M., Franzen, S., et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ, 363, 2018, k4365.
Cahn, A., Melzer-Cohen, C., Pollack, R., Chodick, G., Shalev, V., Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes Metab 21 (2019), 340–348.
Lin, Y.H., Huang, Y.Y., Hsieh, S.H., Sun, J.H., Chen, S.T., Lin, C.H., Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages. Front Endocrinol, 10, 2019, 820.
Iskander, C., Cherney, D.Z., Clemens, K.K., Dixon, S.N., Harel, Z., Jeyakumar, N., et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ, 192, 2020 E351-E60.
Rampersad, C., Kraut, E., Whitlock, R.H., Komenda, P., Woo, V., Rigatto, C., et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. Am J Kidney Dis, 76, 2020 471-9 e1.
Shen, L., Yang, H., Fang, X., Huang, H., Yao, W., Chen, D., et al. A clinical study on the association of sodium-glucose cotransporter 2 inhibitors and acute kidney injury among diabetic Chinese population. Diabetes Metab Syndr Obes 14 (2021), 1621–1630.
Fralick, M., Schneeweiss, S., Redelmeier, D.A., Razak, F., Gomes, T., Patorno, E., Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: an observational study using data from routine care. Diabetes Obes Metab 23 (2021), 950–960.
Delanaye, P., Scheen, A.J., Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: a meta-analysis of observational cohort studies. Diabetes Epidemiol Manag, 2021, 10.1016/j.deman.2021.100021.
Li, W., Katamreddy, A., Kataria, R., Myerson, M.L., Taub, C.C., Sodium-glucose cotransporter-2 inhibitor use is associated with a reduced risk of heart failure hospitalization in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus: a real-world study on a diverse urban population. Drugs Real World Outcomes, 2021;Sep 3, 10.1007/s40801-021-00277-0.
Patorno, E., Pawar, A., Bessette, L.G., Kim, D.H., Dave, C., Glynn, R.J., et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care 44 (2021), 826–835.
Reiffel, J.A., Propensity score matching: the 'devil is in the details' where more may be hidden than you know. Am J Med 133 (2020), 178–181.
Gerstein, H.C., Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. Lancet Diabetes Endocrinol 8 (2020), 557–558.
Sridhar, V.S., Tuttle, K.R., Cherney, D.Z.I., We can finally stop worrying about SGLT2 inhibitors and acute kidney injury. Am J Kidney Dis 76 (2020), 454–456.
Chu, C., Lu, Y.P., Yin, L., Hocher, B., The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press Res 44 (2019), 149–157.
Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 19 (2017), 1106–1115.
Szalat, A., Perlman, A., Muszkat, M., Khamaisi, M., Abassi, Z., Heyman, S.N., Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41 (2018), 239–252.
Horii, T., Oikawa, Y., Kunisada, N., Shimada, A., Atsuda, K., Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: a nationwide cohort study. J Diabetes Investig, 2021, 10.1111/jdi.13630.
Kitamura, K., Hayashi, K., Ito, S., Hoshina, Y., Sakai, M., Yoshino, K., et al. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications. Hypertens Res 44 (2021), 508–517.
Heerspink, H.J.L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol 8 (2020), 27–35.
Scholtes, R.A., van Raalte, D.H., Correa-Rotter, R., Toto, R.D., Heerspink, H.J.L., Cain, V., et al. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. Diabetes Obes Metab 22 (2020), 549–556.
Seidu, S., Kunutsor, S.K., Topsever, P., Khunti, K., Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab, 2021, e00303.
Katsuhara, Y., Ikeda, S., Correlations between SGLT-2 inhibitors and acute renal failure by signal detection using FAERS: stratified analysis for reporting country and concomitant drugs. Clin Drug Investig 41 (2021), 235–243.
Cai, Y., Shi, W., Xu, G., The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. Expert Opin Drug Saf 19 (2020), 1497–1504.
Tian, B., Deng, Y., Cai, Y., Han, M., Xu, G., Efficacy and safety of combination therapy with sodium-glucose transporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis. Nephrol Dial Transplant, 2021, gfab048.
Baker, M., Perazella, M.A., NSAIDs in CKD: are they safe?. Am J Kidney Dis 76 (2020), 546–557.
Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
van Bommel, E.J.M., Muskiet, M.H.A., van Baar, M.J.B., Tonneijck, L., Smits, M.M., Emanuel, A.L., et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97 (2020), 202–212.
Delanaye, P., Wissing, K.M., Scheen, A.J., SGLT2 inhibitors: renal outcomes according to baseline albuminuria. Clin Kidney J, 2021, 10.1093/ckj/sfab096 In press.
Perlman, A., Heyman, S.N., Stokar, J., Darmon, D., Muszkat, M., Szalat, A., Clinical spectrum and mechanism of acute kidney injury in patients with diabetes mellitus on SGLT-2 inhibitors. Isr Med Assoc J 20 (2018), 513–516.
Heerspink, H.J.L., Cherney, D.Z.I., Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol 16 (2021), 1278–1280.
O'Neill, J., Fasching, A., Pihl, L., Patinha, D., Franzen, S., Palm, F., Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309 (2015), F227–F234.
Hesp, A.C., Schaub, J.A., Prasad, P.V., Vallon, V., Laverman, G.D., Bjornstad, P., et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?. Kidney Int 98 (2020), 579–589.
Vinovskis, C., Li, L.P., Prasad, P., Tommerdahl, K., Pyle, L., Nelson, R.G., et al. Relative hypoxia and early diabetic kidney disease in type 1 diabetes. Diabetes 69 (2020), 2700–2708.
Layton, A.T., Vallon, V., Edwards, A., Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol 310 (2016), F1269–F1283.
Laursen, J.C., Sondergaard-Heinrich, N., de Melo, J.M.L., Haddock, B., Rasmussen, I.K.B., Safavimanesh, F., et al. Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine, 37, 2021, 100895.
Darawshi, S., Yaseen, H., Gorelik, Y., Faor, C., Szalat, A., Abassi, Z., et al. Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors. Ren Fail 42 (2020), 836–844.
Saly, D.L., Perazella, M.A., Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol, 313, 2017 F951-F4.
Hallow, K.M., Helmlinger, G., Greasley, P.J., McMurray, J.J.V., Boulton, D.W., Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20 (2018), 479–487.
Ohara, K., Masuda, T., Murakami, T., Imai, T., Yoshizawa, H., Nakagawa, S., et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan. Nephrology 24 (2019), 904–911.
Nassif, M.E., Windsor, S.L., Tang, F., Husain, M., Inzucchi, S.E., McGuire, D.K., et al. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF trial. Diabetes Obes Metab 23 (2021), 1426–1430.
Lytvyn, Y., Bjornstad, P., Udell, J.A., Lovshin, J.A., Cherney, D.Z.I., Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136 (2017), 1643–1658.
Bouquegneau, A., Krzesinski, J.M., Delanaye, P., Cavalier, E., Biomarkers and physiopathology in the cardiorenal syndrome. Clin Chim Acta 443 (2015), 100–107.
Zannad, F., Rossignol, P., Cardiorenal syndrome revisited. Circulation 138 (2018), 929–944.
Chahal, R.S., Chukwu, C.A., Kalra, P.R., Kalra, P.A., Heart failure and acute renal dysfunction in the cardiorenal syndrome. Clin Med 20 (2020), 146–150.
Chang, Y.K., Choi, H., Jeong, J.Y., Na, K.R., Lee, K.W., Lim, B.J., et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS ONE, 11, 2016, e0158810.
Zhang, Y., Nakano, D., Guan, Y., Hitomi, H., Uemura, A., Masaki, T., et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94 (2018), 524–535.